Institut für Pharmazeutische und Medizinische Chemie, Universität Münster, Münster, Germany.
GRK 2515, Chemical biology of ion channels (Chembion), Universität Münster, Münster, Germany.
Arch Pharm (Weinheim). 2024 Sep;357(9):e2400279. doi: 10.1002/ardp.202400279. Epub 2024 Jun 18.
Cyclopenta[g]quinolones of type 4 were designed with the aim to bioisosterically replace the phenol of potent GluN2B ligands such as ifenprodil and Ro 25-6981 by the quinolone system and to restrict the conformational flexibility of the aminopropanol substructure in a cyclopentane system. The designed ligands were synthesized in an eight-step sequence starting with terephthalaldehyde (5). Key steps pf the synthesis were the intramolecular Friedel-Crafts acylation of propionic acids 10 to yield the cyclopenta[g]quinolinediones 11 and the Mannich reaction of diketone 11a followed by conjugate addition at the α,β-unsaturated ketone 12a. Although the quinolones 13a, 15a, and 16a contain an H-bond donor group (secondary lactam) as ifenprodil and Ro 25-6981, they show only moderate GluN2B affinity (K > 410 nM). However, the introduction of lipophilic substituents at the quinolone N-atom resulted in more than 10-fold increased GluN2B affinity of the benzyl and benzyloxymethyl derivatives cis-13c (K = 36 nM) and 13e (K = 27 nM). All compounds are selective over the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA) receptor. The benzyl derivative 13c showed six- and threefold selectivity over σ and σ receptors, respectively.
我们设计了 4 型环戊[g]喹诺酮类化合物,目的是通过喹诺酮系统生物等排取代强效 GluN2B 配体(如ifenprodil 和 Ro 25-6981 的酚),并在环戊烷系统中限制氨基丙醇亚结构的构象灵活性。设计的配体通过从对苯二甲醛(5)开始的八步序列合成。合成的关键步骤是丙酸 10 的分子内傅克酰基化反应,生成环戊[g]喹诺酮二酮 11,以及二酮 11a 的曼尼希反应,然后在α,β-不饱和酮 12a 上进行共轭加成。尽管喹诺酮 13a、15a 和 16a 含有与 ifenprodil 和 Ro 25-6981 相同的氢键供体基团(仲内酰胺),但它们仅显示出中等的 GluN2B 亲和力(K>410 nM)。然而,在喹诺酮 N-原子上引入亲脂性取代基,导致苄基和苯甲氧基甲基衍生物 cis-13c(K=36 nM)和 13e(K=27 nM)的 GluN2B 亲和力增加了 10 倍以上。所有化合物均对 N-甲基-D-天冬氨酸(NMDA)受体的苯环利定(PCP)结合位点具有选择性。苄基衍生物 13c 对 σ 和 σ 受体的选择性分别为六倍和三倍。